- Drugs
- Monday, 27 Apr 2020
Alligator Bioscience Presents Promising Interim Phase I Data for its Bispecific Drug Candidate ATOR-1015 at AACR
Alligator Bioscience, announces that the company today presents the status of the ongoing Phase I clinical trial with the bispecific drug candidate ATOR-1015 developed as tumor-directed therapy for metastatic cancer. The presentation will take place at the AACR (American Association for Cancer Research) Annual Meeting, which this year is being held digital for the first time.
This far, doses of 400 mg (about 6 mg/kg) have been evaluated in the ongoing study and the current dosing is 600 mg (about 10 mg/kg). 18 patients with varying cancer forms (colon cancer, eye melanoma, pancreatic cancer, ovarian cancer, gallbladder cancer, gastric cancer and skin cancer) have been treated and evaluated in terms of safety. ATOR-1015 has so far been well tolerated.
"We are very proud and happy that our study has been selected for presentation. The promising results so far demonstrate that ATOR-1015 can be administered safely. ATOR-1015 has the potential to be at least as effective as today's available treatment for these patients, but with significantly fewer side effects," said Per Norlén, CEO of Alligator Bioscience.
The adverse events in the study were generally mild and transient, all of grade 1 or 2 (on a scale of 1-5). The most common adverse events were infusion-related reactions (five patients). No serious immune-related or dose-limiting adverse events have been reported.
The presentation with the title "A first-in-human phase 1 study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody" will be held by Charlotte Russell, Chief Medical Officer at Alligator Bioscience. The presentation is available through the link below between 9:00 a.m. - 6:00 p.m. EDT (3 p.m.-12 a.m. CEST) today and will also be available on the company website www.alligatorbioscience.com. https://www.abstractsonline.com/pp8/#!/9045/presentation/10644
Related Industry Updates
Applied BioMath, LLC Announces Collaboration with Northern Biologics
Apr 22, 2020
Glenmark Becomes the First Pharmaceutical Company in India to Receive Regulatory Approval for Oral Antiviral Favipiravir, for the Treatment of Mild to Moderate COVID-19
Jun 20, 2020
Shorla Pharma Closes $8.3M Series A Funding Round
Jun 03, 2020
Zongertinib Gains Accelerated FDA Approval as First Oral Targeted Option for HER2-Mutant Lung Cancer
Aug 26, 2025
North America Antibiotics Market Growth and Trends to 2020-2027 With Top Companies Like Johnson & Johnson Services, Inc, Bristol-Myers Squibb Company, Eli Lilly and Company., Abbott, Pfizer Inc
Dec 09, 2020
Eye Drops Market is expected to reach US$ 23,788.4 million by 2030
Aug 09, 2023
Sanofi says COVID-19 vaccine will be available globally at the same time
May 15, 2020
Follow us on
